Growth factors

Worldwide Industry for Erythropoietin to 2030 - Featuring Amgen, Roche and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Pharmaceutical, Health, Growth factors, Branches of biology, Erythropoiesis-stimulating agents, Medical specialties, Clinical medicine, Cytokines, Erythropoietin, Amgen, Epoetin alfa

The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.

Key Points: 
  • The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.
  • Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period.
  • The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years.
  • Global Erythropoietin (EPO) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005506/en/

China Recombinant Human Thrombopoietin Markets, 2015-2020 & 2021-2025 - In 2019, the Market Reached CNY 1257 Million, Representing a CAGR of 40.9% from 2015 to 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Health, Pharmaceutical, Growth factors, Cities in China, Thrombopoietin receptor agonists, Recombinant, Shenyang, Thrombopoietin

Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia.

Key Points: 
  • Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia.
  • In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China.
  • According to this market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China.
  • 2 Sales of Recombinant Human Thrombopoietin in China, 2015-2019
    2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturer of Recombinant Human Thrombopoietin in China, 2015-2019
    3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
    3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China
    4 Prices of Recombinant Human Thrombopoietin in China, 2019-2020
    4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
    5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005489/en/

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Vascular endothelial growth factor, VEGF receptor, Angiogenesis inhibitor, VEGFR-2 inhibitor

The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of vascular endothelial growth factor (VEGF) inhibitor biosimilars.
  • Vascular endothelial growth factor (VEGF)/vascular endothelial growth factor (VEGFR) inhibitors are agents that inhibit VEGF and VEGFR activity.
  • Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity

Retrieved on: 
Monday, February 1, 2021
Branches of biology, Growth factors, Cytokines, Hepatocyte growth factor

When scientists blocked the effects of HGF in ImmCelz treated animals, the therapeutic effects where significantly inhibited.

Key Points: 
  • When scientists blocked the effects of HGF in ImmCelz treated animals, the therapeutic effects where significantly inhibited.
  • The data suggests one of the molecular mechanisms of action of ImmCelz is mediated by production of this therapeutic molecule.
  • Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .

Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

Retrieved on: 
Tuesday, January 19, 2021
Drugs, Clinical medicine, Life sciences, Growth factors, Bevacizumab, Erythropoietin, Biosimilar

Etana is committed to launch BYVASDA in the local market.

Key Points: 
  • Etana is committed to launch BYVASDA in the local market.
  • In return, Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.
  • In January 2020, Innovent entered into an out-license agreement with Coherus BioSciences, Inc. to commercialize BYVASDA (Bevacizumab Biosimilar) in the United States and Canada.
  • The company is currently commercializing EPO in Indonesia for the treatment of anemia in patients with chronic kidney disease.

Eat Beyond Portfolio Company, Singapore's TurtleTree Labs Launches TurtleTree Scientific

Retrieved on: 
Monday, January 11, 2021
Articles, Cellular agriculture, Food and drink, Branches of biology, Meat, Growth factors, Animal welfare, Cultured meat, Epidermal growth factor, Food

VANCOUVER, BC, Jan. 11, 2021 /PRNewswire/ - Eat Beyond Global Holdings Inc. ( CSE: EATS ) ( OTCPK: EATBF ) ( FSE: 988 ) ("Eat Beyond" or the "Company"), an investment issuer focused on the global plant-based and alternative food sector, is announcingthat its portfolio company, TurtleTree Labs has launched TurtleTree Scientific.

Key Points: 
  • VANCOUVER, BC, Jan. 11, 2021 /PRNewswire/ - Eat Beyond Global Holdings Inc. ( CSE: EATS ) ( OTCPK: EATBF ) ( FSE: 988 ) ("Eat Beyond" or the "Company"), an investment issuer focused on the global plant-based and alternative food sector, is announcingthat its portfolio company, TurtleTree Labs has launched TurtleTree Scientific.
  • TurtleTree Scientific is focused on working with cell-based meat companies on the production of food-grade growth factors to build the foundation that the cultured food industry needs to thrive.
  • The same factors, such as EGF, FGF and TGF-B that are used for cell-based milk, can also be used for cell-based meat.
  • "We are very excited about the launch of TurtleTree Scientific and believe that this team has the potential to lead this emerging industry.

TurtleTree Labs, the global leader in cell based milk, launches TurtleTree Scientific

Retrieved on: 
Tuesday, January 5, 2021
Meat, Articles, Cellular agriculture, Food and drink, Life sciences, Biotechnology, Biological engineering, Cultured meat, Science, Growth factors

In early 2021, TurtleTree Scientific will be working with cell-based meat companies on the production of food grade growth factors.

Key Points: 
  • In early 2021, TurtleTree Scientific will be working with cell-based meat companies on the production of food grade growth factors.
  • As an arm of TurtleTree Labs, TurtleTree Scientific will have its own team of experienced industry players driving it.
  • About TurtleTree Scientific- TurtleTree Scientific was founded out of a desire to solve the challenges of cellular agriculture.
  • TurtleTree Scientific is started by TurtleTree Labs and is led by an experienced team of industry professionals.

TurtleTree Labs, the global leader in cell based milk, launches TurtleTree Scientific

Retrieved on: 
Tuesday, January 5, 2021
Meat, Articles, Cellular agriculture, Food and drink, Life sciences, Biotechnology, Biological engineering, Cultured meat, Science, Growth factors

In early 2021, TurtleTree Scientific will be working with cell-based meat companies on the production of food grade growth factors.

Key Points: 
  • In early 2021, TurtleTree Scientific will be working with cell-based meat companies on the production of food grade growth factors.
  • As an arm of TurtleTree Labs, TurtleTree Scientific will have its own team of experienced industry players driving it.
  • About TurtleTree Scientific- TurtleTree Scientific was founded out of a desire to solve the challenges of cellular agriculture.
  • TurtleTree Scientific is started by TurtleTree Labs and is led by an experienced team of industry professionals.

Humanigen to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology, General Health, Health, Clinical trials, Medical specialties, Branches of biology, Clinical medicine, Sarbecovirus, Immunology, Cytokines, Growth factors, Zoonoses, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, Cytokine, Macrophage colony-stimulating factor

We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points: 
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection.
  • The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Global Neutropenia Biologic Drug Treatment Market Report 2020-2030: Focus on COVID-19 Growth, Impact and Changes - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 30, 2020
General Health, Pharmaceutical, Health, Oncology, Medical specialties, Life sciences, Branches of biology, Growth factors, Recombinant proteins, Amgen, Biotechnology, Filgrastim, Lipegfilgrastim, Neutropenia, Biopharmaceutical, Sargramostim

The "Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Neutropenia Biologic Drug Treatment Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global neutropenia biologic drug treatment market.
  • The neutropenia biologic drug treatment market consists of sales of biologics used for the treatment of neutropenia and related services by entities (organizations, sole traders and partnerships) that produce biologics for neutropenia treatment.
  • The neutropenia biologic drug treatment market covered in this report is segmented by drug type into filgrastim; pegfilgrastim; lenograstim; lipegfilgrastim; sargramostim.